MicroRNA in Cardiac Health and Disease
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 20049
Special Issue Editors
Interests: post-transcriptional regulation of gene expression; noncoding RNA; congenital heart disease; animal models
Special Issues, Collections and Topics in MDPI journals
Interests: molecular mechanisms in cardiovascular disease, diabetic retinopathy; idiopathic pulmonary hypertension, thyroid/heart axis; mitochondria physiology and pathophysiology; non coding RNA, animal models
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
High-throughput RNA sequencing technology revealed the key role played by noncoding RNAs as developmental and evolutionary determinants of organismal complexity. MiRNAs are crucial and the most thoroughly characterized component of noncoding RNAs. MiRNAs are ~20–22 nucleotides RNA molecules with post-transcriptionally regulatory roles in almost all physiological and pathological processes. Their evolutionary conservation confirms their importance as regulators, but also eased to get insight into miRNA action mechanisms by exploiting animal models.
Development of heart and cardiac function is a highly spatiotemporal regulated process which actively involves miRNA control. During the last 10 years, alterations in the expression of tens of miRNAs have been described for different cardiovascular diseases (CVDs) such as hypertrophy, arrhythmias, and infarction but also in inherited cardiomyopathies. Modulations in response to stress or disease together with presence in body fluids make miRNAs particularly valuable cardiac biomarkers. More recently, several preclinical studies in animal models demonstrated the possibility to obtain cardioprotective effects by miRNA modulation. Indeed, cardiac microRNAs can affect cardiomyocyte regenerative capacity, inflammatory response or mitochondrial function after myocardial infarction; control pro-survival targets in heart of anthracycline-treated oncologic patients; affect systemic energy homeostasis in metabolic disorders; downregulate hypertrophic response and regulate contractile proteins or Ca homeostasis in cardiomyopathies. These results highlight the therapeutic potential of miRNAs, although many technical obstacles still need to be overcome before they can be approved for CVD treatment in humans.
This Special Issue, entitled “MicroRNA in Cardiac Health and Disease,” of IJMS will cover a selection of recent research topics related to the role of miRNAs in health and disease with a special focus on state-of-the-art miRNA-based therapeutic strategies in CVD. Up-to-date review articles, commentaries, and experimental papers are all welcome.
Dr. Letizia Pitto
Dr. Francesca Forini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MicroRNA
- cardiac biomarker
- cardiac therapeutic target
- heart failure
- arrhythmias
- adverse remodeling
- cardiomyopathy
- cardiovascular risk factors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.